Pharmacogenetic testing for the guidance of psychiatric treatment: A multicenter retrospective analysis

CNS Spectrums

Volumn 22, Issue 4, 2017, Pages 315-324

  Espadaler, Jordi ^a   Tuson, Miquel ^a   Lopez Ibor, Jose Miguel ^b   Lopez Ibor, Franciso ^c   Lopez Ibor, Maria Ines ^d,e  

^a Innovation Department S21sec   (Spain)

^b Instituto López Ibor   (Spain)

^c Quibor   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e Institute PET Dr Carreraas   (Spain)

Author keywords

anxiety; bipolar disorder; depression; genomics; personalized medicine; pharmacogenetics; psychiatric treatment; psychotic disorder

Indexed keywords

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL OUTCOME; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NATURALISTIC INQUIRY; OBSERVATIONAL STUDY; PHARMACOGENETIC TESTING; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SPAIN; ANXIETY DISORDERS; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSIVE DISORDER; MENTAL DISORDERS; MIDDLE AGED; MULTICENTER STUDY; ODDS RATIO; PERSONALIZED MEDICINE; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; TRANQUILIZER;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; ODDS RATIO; PHARMACOGENOMIC TESTING; PRECISION MEDICINE; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPAIN; TREATMENT OUTCOME;

EID: 84973878606     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852915000711     Document Type: Article

References (24)

1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2163-2196.
2. McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011; 31(2): 180-186.
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR,D report. Am J Psychiatry.2006; 163(11): 1905-1917.
4. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR,D Project results: A comprehensive review of findings. Curr Psychiatry Rep. 2007; 9(6): 449-459.
5. Dunner DL, Rush AJ, Russell JM, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006; 67(5): 688-695.
6. Sienaert P, Lambrichts L, Dols A, De Fruyt J. Evidence-based treatment strategies for treatment-resistant bipolar depression: A systematic review. Bipolar Disord. 2013; 15(1): 61-69.
7. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: A review of progress. J Clin Psychiatry. 2010; 71(7): 839-854.
8. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209-1223.
9. Sinclair D, Adams CE. Treatment resistant schizophrenia: A comprehensive survey of randomised controlled trials. BMC Psychatry. 2014; 14: 253.
10. Bijl MJ, Visser LE, Hofman A, et al. Influence of the CYP2D6,4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol. 2008; 65(4): 558-564.
11. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010; 15(5): 473-500.
12. Risselada AJ, Vehof J, Bruggeman R, et al. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: A replication study. Pharmacogenomics J. 2012; 12(1): 62-67.
13. Drozda K, Müller DJ, Bishop J.R. Pharmacogenomic testing for neuropsychiatric drugs: Current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy. 2014; 34(2): 166-184.
14. Hicks JK, Swen JJ, Thorn CF, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther.2013; 93(5): 402-408.
15. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: From bench to byte-an update of guidelines. Clin Pharmacol Ther.2011; 89(5): 662-673.
16. Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron.2008; 57(2): 203-209.
17. Vega M, Sánchez P, Garciá M, et al. Análisis Farmacogenético en psiquiatriá, estudio descriptivo de una experiencia clínica con 21 pacientes. Psiquiatria.com. 2012; 16: 5.
18. Chapman SCE, Horne R. Medication nonadherence and psychiatry. Curr Opin Psychiatry. 2013; 26(5): 446-452.
19. Charland SL, Agatep BC, Herrera V, et al. Providing patients with pharmacogenetic test results affects adherence to statin therapy: Results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. Pharmacogenomics J.2014; 14(3): 272-280.
20. Winner J, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med. 2013; 16(89): 219-227.
21. Hall-Flavin DK, Winner JG, Allen JD, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013; 23(10): 535-548.
22. Winner J, Allen JD, Anthony Altar C, Spahic-Mihajlovic A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry. 2013; 3: E242.
23. Herbild L, Andersen SE, Werge T, Rasmussen HB, Jürgens G. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costsBasic Clin Pharmacol Toxicol. 2013; 113(4): 266-272.
24. Breitenstein B, Scheuer S, Pfister H, et al. The clinical application of ABCB1 genotyping in antidepressant treatment: A pilot study. CNS Spectr.2014; 19(2): 165-175.